STOCK TITAN

PDS Biotechnology Corporation - $PDSB STOCK NEWS

Welcome to our dedicated page for PDS Biotechnology Corporation news (Ticker: $PDSB), a resource for investors and traders seeking the latest updates and insights on PDS Biotechnology Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PDS Biotechnology Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PDS Biotechnology Corporation's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.38%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.83%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.69%
Tags
covid-19
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
PDS Biotechnology Corporation

Nasdaq:PDSB

PDSB Rankings

PDSB Stock Data

140.11M
35.41M
3.67%
22.93%
16.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PRINCETON

About PDSB

pds biotechnology is a clinical stage biopharmaceutical company developing the next-generation of simpler, safer and more effective immunotherapies for cancer and infectious diseases. pds biotechnology’s proprietary versamune® platform vector is based on synthetic and biodegradable lipids which possess a very specific structure and positive charge. the lipids form nanoparticles which activate and are taken up very efficiently by the immune system. the therapeutic product consists of versamune® formulated with a harmless form of the protein or disease-causing agent associated with the particular disease (the antigen) which our immune systems can recognize and respond to. this antigen could be a unique protein expressed only in the cancer cells and not in healthy cells, or it could be a specific viral protein(s) from an infectious virus for example. pds is in the process of completing its first phase 1 human clinical trial in 2015 for pds0101, and has initiated design and preparati